Sibutramine Hydrochloride Monohydrate Articles

Solvay costs and Meridia withdrawal take heavy toll on Abbott Labs 3rd-qtr 2010 results

21 October 2010

Abbott Labs agrees to pull its obesity drug Meridia off US and other markets

11 October 2010

US FDA advisory panel split on keeping Abbott’s obesity drug Meridia on the market

16 September 2010

Abbott Labs gives up on vaccines unit sale, as no adequate bidders in sight; heart risks reported with obesity drug Meridia

6 September 2010

Bad day for slimming pill sibutramine, as EMEA calls for drug’s withdrawal and US FDA for “black box” warning

22 January 2010

USA’s Public Citizen again calls for a ban on Abbott’s obesity drug Meridia

4 December 2009

EMEA starts sibutramine review, as FDA investigates Meridia

23 November 2009

Neurosearch obesity drug fares well in Ph II

10 November 2008

Danger to patients from weak US Rx system: CU

12 December 2005

Sanofi-Aventis' Acomplia will have huge impact on obesity market

6 September 2004

Abbott's sibutramine reduces obesity-associated cardiovascular risks

7 June 2004

UPDATE: Alizyme and Takeda in $42 million obesity drug development deal

18 August 2003

Obesity: "unmet needs create huge potential"

17 March 2003

Abbott gets approval for blockbuster candidate Humira in USA

6 January 2003

Abbott Labs warned over AD reporting

12 August 2002

Abbott Labs reports double-digit growth in 2nd qtr, driven by pharma sales

22 July 2002

CPMP backs safety of Abbott's sibutramine

8 July 2002

UPDATE - CPMP backs safety of Abbott's sibutramine

8 July 2002

Abbott cuts earnings forecasts on plant woes and lower Meridia/Reductil sales

17 June 2002

Abbott faces charges over "withheld data"

3 June 2002

Abbott Labs posts strong 1st-qtr sales and earnings growth

22 April 2002

Abbott posts strong revenue growth for 2001, but charges hit

21 January 2002

Abbott sales up 26% though earnings slip

11 October 2001

Abbott sales up 26% though earnings slip

10 October 2001

Abbott sales growth driven by pharma

13 July 2001

Knoll launches Reductil in UK

24 May 2001

Abbott gets European approval for Knoll's Reductil

5 April 2001

Abbott Labs buying $250 million shares in Millennium as part of metabolic

13 March 2001

BASF sells pharma business to Abbott Labs for $6.9 billion in cash

15 December 2000

BASF wins positive opinion for Reductil in EU

22 November 2000

BASF excited about prospects for D2E7, as rumor mill talks of pharma

15 November 2000

CV benefits with Knoll's sibutramine

6 November 2000

BASF and Hokuriku view pipeline in Japan, envisage 12% contribution by 2005

7 September 2000

BASF reports hugely successful 2nd qtr, with net income up 322.6%

8 August 2000

MSDW explores US prescription sales in major therapeutic areas

6 July 2000

New leading pharma market forecasts to 2009 from Decision Resources

5 July 2000

BASF sets ambitious growth targets for 2000-2002, after positive 1999 trends

16 March 2000

BASF holding onto pharma unit though pressure on for higher profit returns

15 February 2000

Knoll's sibutramine still awaits Euro appros

11 January 2000

BASF profits hit badly by vitamins charge, Meridia sales stagnate

17 November 1999

Xenical, Meridia drive US antiobesity drugmarket

15 November 1999

US DTC advertising spending up 43% in first-half 1999, year-on-year

15 October 1999

BASF Pharma hoping to catch up with top pharmaceutical companies

23 September 1999

BASF Pharma first-half sales up 9% and speeding up

21 September 1999

BASF sees profits collapse as earnings are hit by vitamin price-fixing

6 August 1999

US doctor charged over Internet Rxing offenses

13 July 1999

Euro pharma firms spell out plans for future growth to US investors

17 June 1999

Further increase in Rxs for Roche's Xenical

2 June 1999

Xenical gets off to strong start in USA

13 May 1999

Roche's obesity drug Xenical gains US approval earlier than forecast

27 April 1999

BASF profit warning

16 March 1999

New UK obesity guidelines highlight role of drugs

25 January 1999

First EU approval of Knoll's obesity drug

21 January 1999

Sepracor tops analysts' biotech stocks

20 January 1999

Quality, not quantity, sums up New Chemical Entity launches in 1998

7 January 1999

BASF Pharma Sales Driving Growth

12 November 1998

Fast Growth Seen For BASF's Pharma Unit

7 October 1998

First European Launch Of Xenical In September

4 August 1998

BASF Grows On All Fronts, Pharma Sales Up 21%

4 August 1998

NIH Obesity Guidelines Define Role Of Drugs

25 June 1998

BASF Makes Strong Start To 1998, Sales Up 7.4%

21 May 1998

BASF Not Looking To Sell Pharma Business

30 March 1998

Panel Split On Orlistat Approval For Obesity

16 March 1998

Knoll Starts Distribution Of Meridia For Obesity

13 February 1998

Knoll's High Hopes For Its Obesity Drug Sibutramine

15 January 1998

US Approval For Knoll's Obesity Drug Meridia

27 November 1997

BASF Profits Up But Pharma Growth Down

14 November 1997

Knoll's Meridia Approvable

25 September 1997

BASF Bullish On 1997 As Reflects On 1996

9 April 1997

Roche Enters New Product Phase With Bright Prospects

17 February 1997

BASF/Knoll Considering More Investment In India

20 January 1997

Continued Approval Of Blockbuster Products In '97?

23 December 1996

Knoll's Meridia Approvable In USA

18 November 1996

Roche Highlights Obesity Drug At R&D Conference

21 October 1996

Knoll's Sibutramine Rejected By US Panel

7 October 1996

Boots Buy Boosts BASF In 1996 First Half

2 September 1996

Redux Approved In The USA; Launch In June

6 May 1996

BASF To Introduce 4 New Drugs In 1996-7

8 April 1996

Knoll's Meridia

26 February 1996

Showing 1-79 of 79 articles

Go to beginningPrevious
  • 1
NextGo to end